This image is not available for purchase in your country.

Blinatumomab antibody molecule, artwork

Blinatumomab antibody molecule, artwork

C029/1344

Rights Managed

This image is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

ALFRED PASIEKA / SCIENCE PHOTO LIBRARY ALFRED PASIEKA / SCIENCE PHOTO LIBRARY

Caption

Schematic computer artwork of the monoclonal antibody Blinatumomab, a bi-specific T-cell engager (BiTE). Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.Blinatumomab is used as a second-line treatment against acute lymphoblastic leukemia.

Release details

Model release not required. Property release not required.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Add to board
  • Similar {{ mediaType(i) }}